$SGMO
SANGAMO THERAPEUTICS, INC

2016 Q2 Form 10-Q Financial Statement

#000156459016022708 Filed on August 04, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2015 Q4 2015 Q2
Revenue $3.702M $9.121M $8.358M
YoY Change -55.71% -39.0% -19.52%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.09M $4.890M $5.020M
YoY Change 120.92% 12.93% 26.45%
% of Gross Profit
Research & Development $19.45M $19.91M $15.62M
YoY Change 24.56% 32.82% 16.03%
% of Gross Profit
Depreciation & Amortization $300.0K $300.0K $300.0K
YoY Change 0.0% 200.0% 50.0%
% of Gross Profit
Operating Expenses $30.54M $24.79M $20.64M
YoY Change 48.02% 27.67% 18.37%
Operating Profit
YoY Change
Interest Expense $240.0K $30.00K $150.0K
YoY Change 60.0% -80.0% 114.29%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$26.60M -$15.65M -$12.13M
YoY Change 119.29% 262.27% 73.78%
Income Tax -$20.00K -$1.640M $0.00
% Of Pretax Income
Net Earnings -$26.58M -$14.01M -$12.13M
YoY Change 119.16% 224.45% 73.7%
Net Earnings / Revenue -717.86% -153.63% -145.08%
Basic Earnings Per Share
Diluted Earnings Per Share -$377.1K -$199.7K -$174.1K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2015 Q4 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $172.3M $209.0M $214.2M
YoY Change -19.56% -7.61% 10.58%
Cash & Equivalents $13.00M $69.48M $10.77M
Short-Term Investments $159.3M $139.5M $203.5M
Other Short-Term Assets $1.300M $800.0K $1.200M
YoY Change 8.33% 337.16% 78.84%
Inventory
Prepaid Expenses $754.0K
Receivables $2.300M $2.521M $5.200M
Other Receivables $300.0K $300.0K $400.0K
Total Short-Term Assets $176.2M $212.6M $221.0M
YoY Change -20.29% 11.37% 8.88%
LONG-TERM ASSETS
Property, Plant & Equipment $3.025M $2.916M $3.200M
YoY Change -5.47% 97.16% 97.29%
Goodwill $1.585M $1.585M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $3.900M
YoY Change -90.87%
Other Assets $146.0K $152.0K $200.0K
YoY Change -27.0% 9.35%
Total Long-Term Assets $4.756M $4.653M $8.900M
YoY Change -46.56% -91.11% -81.4%
TOTAL ASSETS
Total Short-Term Assets $176.2M $212.6M $221.0M
Total Long-Term Assets $4.756M $4.653M $8.900M
Total Assets $180.9M $217.2M $229.9M
YoY Change -21.31% -10.68% -8.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.000M $3.905M $9.500M
YoY Change -26.32% -29.32% 66.67%
Accrued Expenses $2.200M $3.100M $2.000M
YoY Change 10.0% -8.82% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.46M $20.10M $21.06M
YoY Change -31.33% -3.76% 25.34%
LONG-TERM LIABILITIES
Long-Term Debt $200.0K $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.200M $4.700M $8.900M
YoY Change -30.34% -68.46% -52.91%
Total Long-Term Liabilities $6.400M $4.700M $8.900M
YoY Change -28.09% -68.46% -52.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.46M $20.10M $21.06M
Total Long-Term Liabilities $6.400M $4.700M $8.900M
Total Liabilities $20.88M $24.80M $30.00M
YoY Change -30.39% -32.21% -17.76%
SHAREHOLDERS EQUITY
Retained Earnings -$412.3M -$369.3M
YoY Change 12.39%
Common Stock $572.3M $561.7M
YoY Change 4.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $160.0M $192.4M $199.9M
YoY Change
Total Liabilities & Shareholders Equity $180.9M $217.2M $229.9M
YoY Change -21.31% -10.68% -8.35%

Cashflow Statement

Concept 2016 Q2 2015 Q4 2015 Q2
OPERATING ACTIVITIES
Net Income -$26.58M -$14.01M -$12.13M
YoY Change 119.16% 224.45% 73.7%
Depreciation, Depletion And Amortization $300.0K $300.0K $300.0K
YoY Change 0.0% 200.0% 50.0%
Cash From Operating Activities -$16.10M -$9.100M -$8.000M
YoY Change 101.25% 237.04% -6.98%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$100.0K -$1.000M
YoY Change -90.0% 150.0%
Acquisitions
YoY Change
Other Investing Activities -$3.800M $45.40M -$7.200M
YoY Change -47.22% -22800.0% -64.71%
Cash From Investing Activities -$3.900M $45.30M -$8.100M
YoY Change -51.85% -11425.0% -61.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -1.000M 1.700M
YoY Change -100.0% -52.38% 0.0%
NET CHANGE
Cash From Operating Activities -16.10M -9.100M -8.000M
Cash From Investing Activities -3.900M 45.30M -8.100M
Cash From Financing Activities 0.000 -1.000M 1.700M
Net Change In Cash -20.00M 35.20M -14.40M
YoY Change 38.89% -776.92% -48.01%
FREE CASH FLOW
Cash From Operating Activities -$16.10M -$9.100M -$8.000M
Capital Expenditures -$100.0K -$100.0K -$1.000M
Free Cash Flow -$16.00M -$9.000M -$7.000M
YoY Change 128.57% 233.33% -14.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-12126000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
70430000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-28000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-30000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5189000
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3025000
CY2016Q2 us-gaap Goodwill
Goodwill
1585000
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
146000
CY2016Q2 us-gaap Assets Current
AssetsCurrent
176150000
CY2015Q4 us-gaap Liabilities
Liabilities
24796000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
703000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
560989000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-369253000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
192439000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
217235000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70354608
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70354608
CY2015Q2 sgmo Collaboration Agreements
CollaborationAgreements
7801000
CY2016Q2 us-gaap Revenue From Grants
RevenueFromGrants
110000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5017000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
30544000
CY2015Q4 us-gaap Goodwill
Goodwill
1585000
CY2015Q2 us-gaap Revenue From Grants
RevenueFromGrants
557000
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8229000
CY2016Q2 us-gaap Revenues
Revenues
3702000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4699000
CY2015Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2748000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2916000
CY2015Q4 us-gaap Assets
Assets
217235000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
152000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
9120000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20097000
sgmo Collaboration Agreements
CollaborationAgreements
7303000
sgmo Collaboration Agreements
CollaborationAgreements
20472000
us-gaap Revenue From Grants
RevenueFromGrants
341000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
212582000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34720000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30598000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16447000
us-gaap Interest And Other Income
InterestAndOtherIncome
305000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-748000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-216000
us-gaap Net Income Loss
NetIncomeLoss
-17445000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-24000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-8000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
126087000
us-gaap Net Income Loss
NetIncomeLoss
-43069000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
510000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1232000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-546000
us-gaap Revenue From Grants
RevenueFromGrants
1377000
us-gaap Revenues
Revenues
21849000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2399000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-36537000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
145890000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
356000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-20159000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
703000
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26567000
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
70487000
CY2016Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
493000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-133000
us-gaap Share Based Compensation
ShareBasedCompensation
10393000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
169000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-56527000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4738000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
247000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
84000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
48000
CY2016Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7014000
CY2016Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2202000
CY2016Q2 us-gaap Assets
Assets
180906000
CY2016Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5244000
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
14460000
CY2016Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
6176000
CY2016Q2 sgmo Build To Suit Lease Obligations
BuildToSuitLeaseObligations
247000
CY2016Q2 us-gaap Liabilities
Liabilities
20883000
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
706000
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
571548000
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-412322000
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
91000
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
160023000
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
180906000
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70606263
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70606263
CY2016Q2 sgmo Collaboration Agreements
CollaborationAgreements
3592000
CY2015Q2 us-gaap Revenues
Revenues
8358000
us-gaap Revenues
Revenues
7644000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19454000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15618000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11090000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-24000
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
69684000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
428000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-464000
us-gaap Share Based Compensation
ShareBasedCompensation
5836000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1800000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
1870000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-748000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
131000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
449000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-833000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3727000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10418000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
120895000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
133235000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2082000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
10258000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
534000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4898000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6030000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4946000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10768000
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
65937000
CY2015Q4 us-gaap Marketable Securities
MarketableSecurities
139518000
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
205455000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
205455000
us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2016Q2 sgmo Other Than Temporarily Impaired Investment
OtherThanTemporarilyImpairedInvestment
0
CY2015Q4 sgmo Other Than Temporarily Impaired Investment
OtherThanTemporarilyImpairedInvestment
0
sgmo Investments Maturity Dates Available For Sale Securities
InvestmentsMaturityDatesAvailableForSaleSecurities
P2Y
CY2015 sgmo Investments Maturity Dates Available For Sale Securities
InvestmentsMaturityDatesAvailableForSaleSecurities
P2Y
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
51000
CY2016Q2 us-gaap Marketable Securities
MarketableSecurities
159321000
CY2016Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
170025000
CY2016Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
169876000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
205440000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. During the first quarter of 2016, we revised the estimated performance period of the upfront Biogen license through June 2019. This change increased net loss by $0.9 million and $1.8 million for the three and six months ended June 30, 2016, respectively. The change in the performance period also increased our basic net loss per share by $0.01 and $0.03 for the three and six months ended June 30, 2016, respectively.</p></div>
CY2016Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
149000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
36000
CY2016Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
170025000
us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2014Q1 sgmo Number Of Research Program
NumberOfResearchProgram
2
CY2016Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
10704000
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7199000
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2883000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10393000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5836000
CY2015Q4 sgmo Build To Suit Lease Property Leased
BuildToSuitLeasePropertyLeased
41400
CY2015Q4 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P5Y
CY2015Q4 sgmo Operating Leases Number Of Extension Options
OperatingLeasesNumberOfExtensionOptions
2
CY2016Q2 sgmo Build To Suit Lease Costs Capitalized
BuildToSuitLeaseCostsCapitalized
200000

Files In Submission

Name View Source Status
0001564590-16-022708-index-headers.html Edgar Link pending
0001564590-16-022708-index.html Edgar Link pending
0001564590-16-022708.txt Edgar Link pending
0001564590-16-022708-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sgmo-10q_20160630.htm Edgar Link pending
sgmo-20160630.xml Edgar Link completed
sgmo-20160630.xsd Edgar Link pending
sgmo-20160630_cal.xml Edgar Link unprocessable
sgmo-20160630_def.xml Edgar Link unprocessable
sgmo-20160630_lab.xml Edgar Link unprocessable
sgmo-20160630_pre.xml Edgar Link unprocessable
sgmo-ex101_285.htm Edgar Link pending
sgmo-ex311_6.htm Edgar Link pending
sgmo-ex312_7.htm Edgar Link pending
sgmo-ex321_9.htm Edgar Link pending
Show.js Edgar Link pending